Bridgeway Capital Management LLC Acquires Shares of 300,000 Heron Therapeutics, Inc. (NASDAQ:HRTX)

Bridgeway Capital Management LLC acquired a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 300,000 shares of the biotechnology company's stock, valued at approximately $459,000. Bridgeway Capital Management LLC owned 0.20% of Heron Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HRTX. Barclays PLC increased its holdings in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock valued at $434,000 after buying an additional 50,109 shares during the period. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after acquiring an additional 154,487 shares in the last quarter. Congress Park Capital LLC boosted its stake in Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after acquiring an additional 477,417 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $76,000. Finally, Capital Planning Advisors LLC boosted its stake in Heron Therapeutics by 41.0% in the fourth quarter. Capital Planning Advisors LLC now owns 106,565 shares of the biotechnology company's stock valued at $163,000 after acquiring an additional 31,003 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Performance

HRTX traded up $0.10 during trading on Friday, hitting $1.97. The stock had a trading volume of 1,254,610 shares, compared to its average volume of 2,320,510. The stock has a 50 day simple moving average of $2.14 and a two-hundred day simple moving average of $1.82. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.93. The company has a market capitalization of $300.55 million, a PE ratio of -10.94 and a beta of 1.33.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. On average, equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HRTX. Needham & Company LLC restated a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.